Genprex Inc - GNPX STOCK NEWS

Genprex, Inc. (NASDAQ: GNPX) announced its participation in NobleCon17, the annual investor conference, on January 19-20. CEO Rodney Varner will present a company overview, with a focus on advancements in clinical trials, at 3:45 p.m. EST on January 19. A video webcast will be available for replay on the company's website post-conference. Notably, Genprex was highlighted in a recent Channelchek report as the most read research report of 2020. The company focuses on innovative gene therapies, including its lead candidate REQORSA™ for non-small cell lung cancer.

Genprex, Inc. (GNPX) announced successful completion of its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy, essential for upcoming Acclaim-1 and Acclaim-2 clinical trials targeting non-small cell lung cancer (NSCLC). All specifications have been met, enabling supply delivery to clinical trial sites pending FDA approval. The technology transfer to commercial CDMOs has been successfully completed. The trials aim to evaluate REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda®, initiating in the first half of 2021.

Genprex (Nasdaq: GNPX) closed a registered direct offering of 3,116,884 shares of common stock at $3.85 per share, yielding gross proceeds of $12 million. The funds will support the Acclaim-1 and Acclaim-2 clinical trials for its gene therapy, REQORSA, in combination with AstraZeneca's Tagrisso and Merck's Keytruda, targeting non-small cell lung cancer. The offering was facilitated by A.G.P./Alliance Global Partners, and no warrants were issued. Net proceeds will be allocated to working capital and corporate purposes.

Genprex, Inc. (Nasdaq: GNPX) has entered into a securities purchase agreement with a healthcare-dedicated institutional investor to sell 3,116,884 shares of its common stock at $3.85 per share. This registered direct offering is priced at-the-market under Nasdaq rules, with no warrants issued. The closing is expected around December 24, 2020, subject to customary conditions. A.G.P./Alliance Global Partners acts as the sole placement agent. The offering is made under an effective shelf registration statement previously filed with the SEC.

Genprex, Inc. (GNPX) has completed the manufacturing scale-up of REQORSA™ immunogene therapy, aimed at supplying the Acclaim-1 and Acclaim-2 clinical trials for non-small cell lung cancer. This production adheres to current Good Manufacturing Practices (cGMP) and includes significant advancements that enhance yield and reduce costs. Upon passing final testing, REQORSA will be stored at controlled temperatures before distribution. These trials will assess REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda® in early 2021, potentially impacting the $26.3 billion lung cancer therapeutics market.

Genprex, Inc. (NASDAQ: GNPX) announced the successful completion of the technology transfer for its lead drug candidate, REQORSA™. This achievement signifies the first commercial-scale production in a cGMP-compliant facility, previously conducted at a major cancer research institution. The company expects enhanced production reliability and scalability, crucial for their upcoming Acclaim-1 and Acclaim-2 clinical trials involving combinations of REQORSA with Tagrisso® and Keytruda®. This milestone represents a significant step forward in Genprex’s drug development efforts.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Benzinga Global Small Cap Conference on December 8. CEO Rodney Varner will provide insights on recent advancements in the Acclaim-1 clinical trial. The virtual event aims to connect small-cap companies with investors, offering opportunities for one-on-one engagement. Genprex focuses on developing innovative therapies for cancer and diabetes, particularly through its lead product, REQORSA™, which targets non-small cell lung cancer. Registration for the conference is available online.

Genprex, Inc. (NASDAQ: GNPX) has begun recruitment for its Acclaim-1 clinical trial targeting non-small cell lung cancer (NSCLC). This Phase 1/2 trial will assess the efficacy of REQORSA™ immunogene therapy combined with AstraZeneca's Tagrisso in late-stage NSCLC patients with EGFR mutations. The trial plans to enroll approximately 100 patients across 10 U.S. sites, with an interim analysis after 53 events. Genprex received FDA Fast Track Designation for this trial, enhancing its market potential.

Genprex, Inc. (NASDAQ: GNPX) announced its participation in the Diamond Equity Research Emerging Growth Invitational, set for December 1, 2020, at 11:40 a.m. EST. Executive Vice President Michael Redman will present a company overview and engage in a Q&A session. The virtual event aims to showcase Genprex's advancements in gene therapies for cancer and diabetes. The company's leading drug candidate, REQORSA™, is in development for non-small cell lung cancer and has received Fast Track Designation from the FDA. More details can be found on Genprex's website.